Branch Therapeutics is redefining how cancer recurrence and treatment resistance are addressed by targeting the convergent signaling networks that sustain cancer stem cells and tumor growth.

Our first-in-class, orally available dual-kinase inhibitors are rationally designed to coordinately modulate WNT/β-catenin and PI3Kα signaling, interconnected pathways that drive proliferation and enable cancer stem cell survival, self-renewal, and adaptive resistance. Built alongside a robust precision biomarker strategy, our therapies are engineered to be combination-ready, advancing a new vision for potentially safer and longer-lasting responses in solid tumors.